Radiation
Radiation Therapy for Breast Cancer
This trial is testing whether adding a tumour bed boost after breast conserving surgery (BCS) in women with non-low risk ductal carcinoma in situ (DCIS) reduces the risk of local recurrence. There are two fractionation arms in this trial: a shorter fractionation arm and a standard fractionation arm. The overall objectives of the trial are to improve the outcome of women with non-low risk DCIS treated with BCS and to individualize treatment selection for women with DCIS to achieve long term disease control with minimal toxicity.
Radiation Therapy
Intraoperative Radiotherapy for Breast Cancer
This trial will look at using Intraoperative Radiotherapy (IORT) to treat Ductal Carcinoma In-Situ (DCIS). Researchers want to learn more about how well it works and what effects it has on patients.
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Precancerous Breast Conditions
This trial is testing if ruxolitinib can change early abnormal breast cells that might turn into cancer. Some participants will take the drug for a short period, while others will not. Afterward, all participants will have surgery to remove the abnormal cells. Ruxolitinib has been evaluated in various clinical trials for treating certain types of breast cancer.
Procedure
Surgery vs Active Monitoring for Low-Risk Ductal Carcinoma In Situ
This trial compares regular check-ups to surgery for women with low-risk Ductal Carcinoma in Situ (DCIS). The goal is to see if monitoring the condition without immediate surgery can provide similar outcomes in terms of cancer control and quality of life. Surgery can lead to persistent pain and other issues, so avoiding it might benefit patients. The study is examining the safety of monitoring low-risk DCIS without surgery.
Popular Filters
Trials for DCIS Patients
Cancer Vaccine
MUC1 Vaccine + Aromatase Inhibitor for Breast Cancer
This trial is enrolling post-menopausal women with a condition called DCIS. There are two groups in the trial. One group will receive a medication called an aromatase inhibitor for about
Hormone Therapy
Hormonal Therapy for Early-Stage Breast Cancer
This trial is testing if hormonal therapy & monitoring can manage early-stage breast cancer effectively. Participants get treatment & MRI exams, plus provide samples to study immune & genetic factors.
Cancer Vaccine
H2NVAC Vaccine for Breast Cancer
This trial studies the H2NVAC vaccine, which aims to boost the immune system to fight breast cancer in patients with HER2-expressing DCIS. The vaccine helps the body recognize and attack cancer cells by targeting the HER2 protein. H2NVAC is a vaccine targeting the HER2 protein, similar to other HER2/neu vaccines being tested for their ability to elicit immune responses against breast cancer.
Trials for Ductal Carcinoma Patients
Cancer Vaccine
MUC1 Vaccine + Aromatase Inhibitor for Breast Cancer
This trial is enrolling post-menopausal women with a condition called DCIS. There are two groups in the trial. One group will receive a medication called an aromatase inhibitor for about
Hormone Therapy
Hormonal Therapy for Early-Stage Breast Cancer
This trial is testing if hormonal therapy & monitoring can manage early-stage breast cancer effectively. Participants get treatment & MRI exams, plus provide samples to study immune & genetic factors.
Trials for ER Positive Patients
Cancer Vaccine
MUC1 Vaccine + Aromatase Inhibitor for Breast Cancer
This trial is enrolling post-menopausal women with a condition called DCIS. There are two groups in the trial. One group will receive a medication called an aromatase inhibitor for about
Hormone Therapy
Hormonal Therapy for Early-Stage Breast Cancer
This trial is testing if hormonal therapy & monitoring can manage early-stage breast cancer effectively. Participants get treatment & MRI exams, plus provide samples to study immune & genetic factors.
Radiation
Partial Breast Irradiation for Early Stage Breast Cancer
This trial looks at how well a shorter, higher-dose radiation therapy works to treat early stage breast cancer. The cancer is only in the breast, and this treatment may have fewer side effects.
Trials With No Placebo
Cancer Vaccine
MUC1 Vaccine + Aromatase Inhibitor for Breast Cancer
This trial is enrolling post-menopausal women with a condition called DCIS. There are two groups in the trial. One group will receive a medication called an aromatase inhibitor for about
Hormone Therapy
Hormonal Therapy for Early-Stage Breast Cancer
This trial is testing if hormonal therapy & monitoring can manage early-stage breast cancer effectively. Participants get treatment & MRI exams, plus provide samples to study immune & genetic factors.
Cancer Vaccine
H2NVAC Vaccine for Breast Cancer
This trial studies the H2NVAC vaccine, which aims to boost the immune system to fight breast cancer in patients with HER2-expressing DCIS. The vaccine helps the body recognize and attack cancer cells by targeting the HER2 protein. H2NVAC is a vaccine targeting the HER2 protein, similar to other HER2/neu vaccines being tested for their ability to elicit immune responses against breast cancer.
View More Related Trials
Frequently Asked Questions
Introduction to dcis
What are the top hospitals conducting dcis research?
In the quest to better understand and treat ductal carcinoma in situ (DCIS), several hospitals have taken on the challenge with remarkable dedication. Anchorage's Providence Alaska Medical Center leads the way with three active clinical trials focused specifically on DCIS, along with a history of four completed trials since their first recorded study back in 2008. Not far behind is Northwestern University in Chicago, where researchers are currently engaged in two ongoing DCIS trials while having made significant strides through thirteen previous studies dating back to 2008.
Meanwhile, Cleveland Clinic has also made notable contributions to DCIS research, conducting two active clinical trials and building upon their three past investigations since embarking on this journey in 2015. Interestingly enough, Anchorage seems to be carving out its own niche as a hub for DCIS studies. Two local institutions—Alaska Breast Care and Surgery LLC and Alaska Women's Cancer Care— are actively involved in two concurrent clinical trials each, adding up respectively to four all-time investigations conducted by both facilities since they initiated their first-ever trial focused on DCIS exactly twelve years ago.
These dedicated hospitals demonstrate that advancements can come from unexpected places when it comes to medical breakthroughs. The shared commitment among these institutions reflects not only an eagerness to unravel the complexities of DCIS but also a testament to the power of collaborative efforts within medical communities across different locations. With every trial conducted and knowledge gained about this condition, we move one step closer towards offering improved treatment options and ultimately striving for prevention strategies that will benefit patients worldwide facing or at risk for developing ductal carcinoma in situ.
Which are the best cities for dcis clinical trials?
When it comes to DCIS (Ductal Carcinoma In Situ) clinical trials, several cities stand out as leading hubs for research and development. Anchorage, Alaska and Denver, Colorado are tied with 14 active trials each, focusing on innovative treatments like Hypofractionated Radiation Therapy, Trastuzumab, Active Monitoring, and more. Los Angeles, California follows closely behind with 12 ongoing studies exploring treatment options such as Trastuzumab and Hypofractionated Radiation Therapy. Additionally, Oakland and Sacramento in California offer promising opportunities for participation in DCIS clinical trials. These cities provide individuals diagnosed with DCIS access to cutting-edge research that can pave the way for improved care and outcomes in managing this condition.
Which are the top treatments for dcis being explored in clinical trials?
In the world of clinical trials, several promising treatments are being explored for ductal carcinoma in situ (DCIS). These include:
-
Intraoperative Imaging: Currently undergoing one active trial, with a total of one DCIS trial recorded since its debut in 2022.
-
Cryoablation: Showing promise, cryoablation is involved in one ongoing trial, and has been featured in two all-time DCIS trials since 2016.
-
Multi-epitope HER2 Peptide Vaccine H2NVAC: Also making waves is this vaccine, currently participating in one active trial and having its first listing back in 2019.
-
Hypofractionated Radiation Therapy: A notable contender on the list with a history dating back to 2011. This treatment is engaged in one active DCIS trial while accumulating three all-time trials.
What are the most recent clinical trials for dcis?
Recent clinical trials for ductal carcinoma in situ (DCIS) offer promising developments in the field of breast cancer research. One notable study focuses on intraoperative imaging, aiming to enhance surgical precision and improve outcomes for patients with DCIS. Another trial explores the potential of a multi-epitope HER2 peptide vaccine, H2NVAC, as a novel immunotherapy approach for DCIS treatment. Additionally, researchers are investigating the efficacy and safety of ruxolitinib, an innovative drug that may have therapeutic benefits specifically for individuals with DCIS. These groundbreaking trials shed light on new strategies to combat this condition and provide hope for improved management and care in the future.
What dcis clinical trials were recently completed?
Recent clinical trials for ductal carcinoma in situ (DCIS), the earliest form of breast cancer, have shown promising results. In June 2018, the National Cancer Institute successfully completed a trial investigating the potential of Bexarotene as a treatment option. Similarly, G1 Therapeutics conducted a trial testing G1T48 and concluded it in May 2018. These advancements represent significant strides towards improving our understanding and management of DCIS. The completion of these trials highlights ongoing efforts to develop innovative therapies that could potentially transform the lives of individuals diagnosed with this condition.